TickerFacts.

Artiva Biotherapeutics, Inc. (ARTV): Depreciation & Amortization

Annual figures by period end, from SEC filings.

$2.60M
Year ended 2025-12-31
$2.69M
Trailing 12 months to 2026-06-30
2023-12-31: $2.27M2024-12-31: $2.43M2025-12-31: $2.60M$2.60M
2023-12-31 Depreciation & Amortization (USD) 2025-12-31
Period endedDepreciation & AmortizationChange YoYSource filing
2025-12-31$2.60M+6.8%2026-03-10, From 2025-01-01
2024-12-31$2.43M+7.3%2026-03-10, From 2024-01-01
2023-12-31$2.27Mn/a2025-03-24, From 2023-01-01

Depreciation & Amortization at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedDepreciation & AmortizationChange YoY
Artiva Biotherapeutics, Inc. (ARTV)2025-12-31$2.60M+6.8%
Vaxart, Inc. (VXRT)2025-12-31$8.58M-3.1%
Amgen Inc (AMGN)2025-12-31$5.17B-7.6%
Repligen Corp (RGEN)2025-12-31$78.75M+13.0%
Champions Oncology, Inc. (CSBR)2026-04-30$1.38M-16.0%
Bio-Techne Corp (TECH)2026-06-30$97.36M-11.4%
Biogen Inc. (BIIB)2025-12-31$779.90M+15.8%
Lineage Cell Therapeutics, Inc. (LCTX)2025-12-31$699.0K+19.1%
BioCryst Pharmaceuticals Inc (BCRX)2025-12-31$1.39M+11.5%

Compare ARTV, VXRT, AMGN, RGEN side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗